AMARIN CORP PLC\UK
AMRNDrugs in Pipeline
6
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Ethyl-EPA (Miraxion™)
Huntington Disease
AMR101 (ethyl icosapentate) - 4 g/day
Hypertriglyceridemia
AMR101 (ethyl icosapentate) - 2 g/day
Hypertriglyceridemia
AMR101
Cardiovascular Diseases
Icosapent ethyl (IPE)
COVID19
Icosapent ethyl
COVID-19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ethyl-EPA (Miraxion™) | Phase 3 | Huntington Disease | - | - |
AMR101 (ethyl icosapentate) - 4 g/day | Phase 3 | Hypertriglyceridemia | - | - |
AMR101 (ethyl icosapentate) - 2 g/day | Phase 3 | Hypertriglyceridemia | - | - |
AMR101 | Phase 3 | Cardiovascular Diseases | - | - |
Icosapent ethyl (IPE) | Phase 3 | COVID19 | - | - |
Icosapent ethyl | Phase 3 | COVID-19 | - | - |
cardiovascular
1 drug in this indication
Secondary prevention of cardiovascular events
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in AMARIN CORP PLC\UK's drug pipeline?→
CatalystAlert tracks 6 drug candidates in AMARIN CORP PLC\UK's (AMRN) pipeline across Phase 3. Its lead program is Ethyl-EPA (Miraxion™) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AMARIN CORP PLC\UK's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for AMARIN CORP PLC\UK (AMRN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AMRN biotech catalysts?→
Add AMRN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AMARIN CORP PLC\UK's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.